IFI30 and diffuse large B-cell lymphoma: Elevated expression levels of IFI30 have been associated with improved patient survival in several cancers, including diffuse large B‐cell lymphoma [13], gastroesophageal junction adenocarcinoma [14], melanoma [7, 15], and cervical cancer [16].